Wilmington Savings Fund Society, FSB 13F: Cuts JNJ Stake by $8.5M
Key Points
- Wilmington Savings Fund Society trimmed its Johnson & Johnson position by 32,098 shares during the quarter, bringing its total holding to 316,845 shares worth about $83.9 million.
- Johnson & Johnson shares recently traded around $263.85, sitting about 6.1% below their 52-week high of $281.07 while offering a 2.0% dividend yield.
- Other large fund managers adjusted their stakes, with BSN Capital Partners adding 282,000 shares and Capital Investment Advisors trimming 15,883 shares.
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Wilmington Savings Fund Society lowered its stake in Johnson & Johnson NYSE: JNJ during the quarter, cutting its holdings by 32,098 shares to finish with 316,845 shares. The quarterly institutional holdings report filed with the U.S. Securities and Exchange Commission on October 23, 2026, values the remaining stake at approximately $83.9 million. The prior holding stood at 348,943 shares, representing a 9.2% decrease for the fund.
JNJ
Johnson & Johnson
What Changed in Wilmington Savings Fund Society's Johnson & Johnson Position
The fund trimmed its exposure to the healthcare giant by 9.2%, reducing its share count from 348,943 down to 316,845 shares.
Other Institutional Activity in Johnson & Johnson
Other large financial institutions also adjusted their positions in the healthcare firm around the same reporting period. BSN Capital Partners added 282,000 shares, ending with 282,000 shares worth about $75.9 million. Capital Investment Advisors reduced its position by 15,883 shares, ending with 398,735 shares valued at roughly $105.6 million. Meanwhile, State Farm Mutual Automobile Insurance Co kept its massive stake steady at 315,909,520 shares worth about $8.33 billion.
Johnson & Johnson Stock Up 2.4%
Johnson & Johnson shares recently traded around $263.85 as of October 24, 2026, virtually even with the $263.81 close on the filing date. The stock sits about 6.1% below its 52-week high of $281.07 and roughly 42.9% above its 52-week low of $184.66. The current price also rests about 7.6% above its 200-day moving average of $245.19, reflecting solid longer-term momentum despite trading slightly below its average analyst price target of $279.41.
Recent Earnings
The company generated $99.3 billion in trailing twelve-month revenue alongside a net profit margin of 16.2%. Earnings per share over the same period reached $6.59, and the firm reported year-over-year revenue growth of 5.9%. The next quarterly earnings report is scheduled for release on January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend rate of $5.36 per share, which translates to a 2.0% dividend yield based on recent trading levels. The company maintains a dividend payout ratio of 80.1%.
Insider Buying and Selling at Johnson & Johnson
Company insiders executed several stock sales prior to the filing. Officer Elizabeth Forminard sold 15,918 shares valued at approximately $4.1 million on August 6, 2026. Chief Executive Officer Joaquin Boix Duato sold 123,291 shares worth about $32.2 million on August 13, 2026. Officer Jennifer L Taubert sold 15,000 shares at $263.36 apiece for a total of $4.0 million on August 17, 2026. Finally, Officer Timothy Schmid sold 33,597 shares at $274.74 each, totaling $9.2 million on September 2, 2026.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock through mid-October 2026. Leerink Partners maintained its Outperform rating while adjusting its price target from $276.00 to $272.00 on October 14, 2026. Wells Fargo maintained an Overweight rating, lowering its target from $282.00 to $275.00 on the same day, before later raising it to $287.00 on October 16, 2026. RBC Capital maintained an Outperform rating with a target moved from $290.00 to $280.00 on October 14, 2026. Morgan Stanley maintained an Overweight rating while shifting its target from $294.00 to $292.00 on October 15, 2026. Overall, the stock carries a consensus buy recommendation among 22 analysts.
About Johnson & Johnson
Johnson & Johnson operates as a global healthcare company, researching, developing, and manufacturing a wide variety of medical products and pharmaceuticals. The enterprise runs through two primary divisions: Innovative Medicine and MedTech. Institutional adjustments like this filing give a window into how major professional managers balance large health sector holdings.
Bottom Line
Wilmington Savings Fund Society's reduction reflects minor portfolio rebalancing rather than a shift in business fundamentals. Investors will watch for the upcoming earnings report on January 26, 2027, to check ongoing revenue trends across the Innovative Medicine and MedTech segments.
Related Filing Alerts
Source: Wilmington Savings Fund Society, FSB's 13F filing on $JNJ (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts